


Macrolides

The macrolide family ...



erythromycin

- **roxithromycin**
- **clarithromycin**
- **dirithromycin**


• **telithromycin**

azithromycin


josamycin
spiramycin
miocamycin

Coming soon !!

Erythromycin: mode of action



Erythromycin: mode of action



Erythromycin: spectrum of activity

Erythromycin A : mostly Gram (+) organisms

Plus:

- *Legionella p.*
- *Chlamydia spp.*
- *Mycoplasma spp.*
- *Mycobacterium avium*

Erythromycin - MIC distributions of isolates that lack resistance mechanisms

Mg/L	.004	.008	.016	.032	.064	.125	.25	.5	1	2	4	8	16	32	<u>>64</u>
<i>S.aureus</i>					●	●	●	●							
<i>Coag-neg staph</i>				●	●	●									
<i>S.saprophyticus</i>			●	●	●										
<i>Streptococcus_A</i>			●	●	●										
<i>Streptococcus_B</i>			●	●	●										
<i>Pneumococci</i>			●	●	●										
<i>Strept misc</i>		●		●	●	●	●								
<i>Enterococcus</i>						●	●		●	●	●	●			
<i>Listeria</i>						●	●		●						
<i>Corynebacteria</i>			●	●	●										
<i>Bacillus spp</i>		●	●	●											
<i>H.influenzae</i>								●	●	●	●	●			AST
<i>M.catarrhalis</i>					●	●	●								
<i>B.pertussis</i>						●	●		●	●					
<i>P.multocida</i>											●	●	●		
<i>L. pneumophila</i>						●	●		●	●					
<i>Camp. jejuni</i>						●	●		●						
<i>N.gonorrhoeae</i>			●		●	●	●								
<i>N.meningitidis</i>						●	●	●		●					
<i>M.pneumoniae</i>	●	●	●	●											
<i>Borr. burgdorferi</i>					●	●	●								

SRGA and SRGA-M, 1998-04-13, 2001-11-11

G Kahlmeter & B.Olsson-Liljequist


Erythromycin: the problems

Erythromycin A


14 atoms

Instability in acid media

Keto in C9




Alcohol in C6




Inactive antibiotic


Erythromycin: details of acid the degradation



What have the chemists done to avoid acid-instability?




What have the chemists done to avoid acid-instability ?



acid stability

Did these modifications change anything else in PK ?



pharmacokinetic differentiation

A large green arrow points to the right, followed by the text "pharmacokinetic differentiation" in a large, bold font.

Did these modifications change anything else ?

Cytochrome P₄₅₀ interactions

erythromycin A

**clarithromycin
roxithromycin**

dirithromycin

azithromycin

+++++

Drug interactions with macrolides

- The main problem due to interactions between some macrolides and the cytochrome P 450 system, especially the CYP3A subclass of enzymes
- Finally results in lowered metabolism of CYP3A-dependent drugs

drug	azi	clari	diri	ery	josa	mid	roxi	spira
théophyllin	0	0	0	++	+	ND	0/+	0
ciclosporin	ND	ND	ND	+++	+++	+++	+	0
carbamazepin	ND	0/+	ND	+++	+	+	0/+	0/+
midazolam	0	++	ND	++	ND	ND	+	ND
warfarin	0	ND	ND	+	ND	ND	0	ND
terfenadin	0	++	ND	+++	0/+	ND	0	ND
cisapride	ND	++	ND	++	++	ND	ND	0

From Petitjean et al.

N=undocumented

Mainly considered as a class-effect, resulting from what is known for erythromycin, except for spira and azithromycin

Basic indications of (classical) macrolides in a world of no resistance

erythromycin

clarithromycin

roxithromycin

dirithromycin

azithromycin

Respiratory tract infections

- pharyngitis
- otitis
- sinusitis
- acute exacerbations of chronic bronchitis
- community acquired pneumonia
- legionellosis
- *C. pneumoniae*
- *Mycobacterium avium* (AIDS)

Genital/Ocular infections

- chlamydiosis (*C. trachomatis*)
- syphilis
- donovanosis
- gonorrhoea

Gastric ulcer (*H. pylori*)

Which is the best ?

erythromycin

clarithromycin

roxithromycin

dirithromycin

azithromycin



But was has been the problem ?


erythromycin

clarithromycin

roxithromycin

dirithromycin

azithromycin



Emergence of resistance

Target modification: erm


Efflux: Mef

All are similarly affected

Mechanisms of macrolide resistance


- **Ribosomal modification by methylase (*erm* genes)**
 - *S. pneumoniae*: *erm*(B) 75-100% of Ery-R strains in Europe
 - *S. pyogenes*: *erm*(B) generally <50% of Ery-R strains
erm(A)
- **Ribosomal modification by mutation (rRNA, proteins)**
 - Occasional in Ery-R *S. pneumoniae*
 - Rare in Ery-R *S. pyogenes* (up to 18% in Eastern Europe)
 - The only mechanism or highly prevalent in *H. pylori*,
Campylobacter, *M. avium*
- **Drug efflux (*mef* genes)**
 - <25% in Ery-R *S. pneumoniae*
 - >50% in Ery-R *S. pyogenes* (up to 95%)

Correlation between erythromycin MICs and resistance mechanisms




Nagai ICAAC 2000, abstr # 892

One example: the evolution of *S. pneumoniae* resistance in Belgium between 1985 and 2000



J. Verhaegen, Central Pneumocci Reference Laboratory, Louvain

The Alexander Project 1999: *S. pneumoniae*, Macrolide Resistance




Distribution of erythromycin-resistance phenotypes among pneumococci from 8 different European countries (1998-2000)

Country (total N of isolates)	ref	overall % of erythromycin-resistance	distribution of resistance phenotype		
			MLS _B	M	other
Belgium (59)	1	31	91.5	8.5	0
Finland (651)	2	11.2	71	21	11.2
France (48)	3	53	100	0	0
Germany (102)	4	10.6	74	22.5	3.5
Greece (140)	5	18	67.9	29.2	3.6
Italy (85)	6	31.7	76.5	23.5	0
Norway (8)	7	4.5	75	25	0
Spain (109)	8	36.1	84	15	1


- Bronchitis
- pneumonia
- sinusitis
- otitis


Resistance to macrolides in Greece



Inhibition of Protein Synthesis (1)

- Inhibition of peptidyl transferase activity





Resistance: a semi-rational answer ...

erythromycin A

C₃-descladinose

ketolides

lateral basic
hydrophobic
chain to
increase activity

→ **telithromycin**


C₆-methoxy
for acid-stability

Target modification: ermA

Efflux: Mef E

Inhibition of Protein Synthesis (2)

- Inhibition of peptidyl transferase activity




MIC₅₀ [µg/ml] of wild type and mutant strains

		Erythromycin	Telithromycin
<i>S. pyogenes</i>	(WT)	0.03	0,08
	(<i>ermTR</i> ind.)	4	0,06
	(<i>ermTR</i> const.)	>64	0,25
	(<i>ermB</i> ind.)	>64	0,5 - 1
	(<i>ermB</i> const.)	>64	8
	(<i>mef</i>)	8	0,5 ←
<i>S. pneumoniae</i>	(WT)	0,03	0,008
	(<i>ermB</i> const.)	>64	0,06
	(<i>mef</i>)	2	0,125

Telithromycin

- Telithromycin, the first ketolide, was designed to overcome erythromycin A resistance within Gram (+) positive cocci and take advantage of PK improvements of clarithromycin



Pharmacokinetics of telithromycin

(as submitted to the FDA; april 2001)

	800 mg (single dose)	800 mg (7 days)
C_{max} (mg/L)	1.9 (42)	2.3 (31)
C_{24h} (mg/L)	0.03 (45)	0.07 (72)
AUC_{24h} (mgxh/L)	8.3 (31)	12.5 (43)
$t_{1/2}$ (h)	7.2 (39)	9.8 (20)


**The company has declared
that activity of telithromycin is
driven by C_{max} /MIC and by
 AUC_{24h} /MIC ratios**

Pharmacodynamics of telithromycin (as based on FDA submission; april 2001)

Organism	MIC ₉₀	C _{max} /MIC _{90max}	AUC _{24h} /MIC _{90max}
S. pneumoniae	< 0.008 - 0.25	7.6	33.2
S. pyogenes	< 0.015 - 0.06	31.6	138
H. influenzae	2.0 - 4.0	0.475	2.075
M. catarrhalis	0.12	15.8	69.1
L. pneumophila	0.03 - 0.12		
C. pneumoniae	0.03 - 2		
M. pneumoniae	0.25		

Activity will be good for MIC≤ 0.25 mg/L, but may become problematic for higher MICs

Which are the sensitivities of *S. pneumoniae* towards telithromycin in Belgium in 2000 ?



MIC_{90} for Ery-s strains: < 0.06 ...

But MIC_{90} for Ery-r strains: 0.25-0.5 ...

Verhaegen & Verbist, Acta Clin. Belg. 2001, 56: 351

Macrolides: the 16 atoms family

Erythromycin A

14 atoms




Carbomycin A / Spiramycins

16 atoms

Intrinsically
acid-stables

Macrolides: the 16 atoms family

► 16 ATOMS



josamycin

$\text{R1} = \text{COCH}_3 / \text{R2} = \text{H} / \text{R3} = \text{H} / \text{R4} = \text{COCH}_2\text{CH}(\text{CH}_3)_2$


miocamycin

$\text{R1} = \text{COCH}_2\text{CH}_3 / \text{R2} = \text{COCH}_3 / \text{R3} = \text{COCH}_3 / \text{R4} = \text{COCH}_2\text{CH}_3$

spiramycin

$\text{R1} = \text{H} / \text{R2} = \text{CO}(\text{CH}_2)_2\text{CHCHOHCH}_3 / \text{R3} = \text{H} / \text{R4} = \text{H}$

Properties of the 16 atoms family



Low cyt P450 interactions

Non ermB inducers

Non mefE substrates

But, usually, lower
intrinsic activities

Intrinsically
acid-stables

Macrolides: the present family picture

